Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Loaded up these cheapies hopefully we close nicely
Other news: ZLCS +51.9% (Epirus Biopharmaceuticals announced positive data from a Phase 3 trial of BOW015 in patients with active rheumatoid arthritis; ZLCS entered into an agreement and plan of merger with Epirus on April 15)
Only news fees I found from briefing centre in the morning
Hoping we hear from Zalicus soon
Definitely think they will by day end or tomorrow.
Nevertheless anything at this range after these results and data are an outright bargain.
THIS SHOULD HAVE BEEN PR'D BY NOW WHY ARE THEY WAITING
Should see ZLCS 1.65-1.80 by end of day
After the profit takers move on and out
So undervalued
a $8.7 Billion drug here!!
Zalicus- ZLCS- LARGEST % GAINER
Awesome news today
FDA approval no time
We're talking a $8.7 Billion drug here!!
Here's the news released last night by Zalicus's partner Epirus that shows superiority over J&J's drug Remicade:
http://www.epirusbiopharma.com/investors/investors-press-releases-2014-06-11.php
And here's the Link to the market potential (scroll down the page and look for Remicade sales in 2013):
http://www.usatoday.com/story/money/markets/2013/10/22/three-best-selling-drugs/3149997/
Thanks - will keep an eye on this one
Arthritis drug news with their partner, PH 3 study, it works
$ZLCS - why is this up big AH ?
I am glad sold out yesterday at $1.52.
Too many old bag holders + BATS Diluter
this one is diluting a lot. passed
How safe is it to go long on this one? I've read old posts and it has been volatile. When it merges will the do a backward split or something? Will a person loose stocks when they change their name? I'd like to load up but I wanted to hold onto it and see how high they go. How safe is it to do that with this stock? I'm asking those that have watched this one for awhile. I'm a newbie. I have lost tons of cash. Trying to win some back now.
Diamond
Told you to be careful Bra! Move those remaining profits to BCCI! Thank me later $$$$$$$$$
Too many old bag holders it looks like sold $1.42
Too many 25k and 40k blocks being slammed on the ask.
Move your profits to BCCI about to run! Choo Choo $$$$$$$$$$
That's how you make money on a spike! congrats!
Be careful! GLTY ill be watching in the sidelines!
I use to have that kind of gung ho mentality; at first it was a blast making tons of money then after a while reality caught up to me! LOL
22K @ $1.45 go big or go home lol
it's just $$$$ gotta have a stomach....STL $1.38.
I guess you got in pretty high??? H&S forming again like wavx!
Hate this rocketship formation; very volatile a lot of traders are going in & out! profit taking has began! I'll be waiting for lunch again! LOL
Quick flip in at $1.25 out at $1.65
Building a nice base $1.40+
A lot of selling! will watch first!
Just filled 15k @ $1.45. Will fill another 15K @ $1.35 if it dips there.
Looking the same chart as WAVX one day runner!
waiting for it to dip back to 1.35 LOL
pre market $1.28 Been holding this stock for a long time look's like PAY DAY is here with the merger news.
Sold ZLCS this week for nearly a 70% gain
Form 8-K for ZALICUS INC. http://finviz.com/quote.ashx?t=zlcs
7-Feb-2014
Change in Directors or Principal Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On February 3, 2014, Mr. Jason Cole, Executive Vice President, Corporate Development and General Counsel, provided notice to Zalicus Inc. (the "Company") of his intention to resign from the Company effective as of March 5, 2014 to pursue a new career opportunity.
Exalgo Royalties Monetized
On February 3, 2014, Zalicus Inc. (ZLCS) filed a Form 8K announcing the sale of all rights to future royalties on sales of Exalgo at Mallinckrodt Inc. in return for $7.2 million in cash. Zalicus originally entered into a licensing agreement with Mallinckrodt for Exalgo, an extended release formulation of hydromorphone hydrochloride, in June 2009. Exalgo was approved for sale in the U.S. in March 2010 and launched by Mallinckrodt in April 2010. To date, Zalicus has received $16.0 million in royalties relating to sales of Exalgo at Mallinckrodt. In the fourth quarter 2013, royalties on Exalgo totaled $2.0 million to Zalicus.
We believe the transaction was a wise one for Zalicus because Exalgo's days of exclusivity are nearing an end. Pending final U.S. approval for the generic formulation, generic manufacturer, Actavis, Inc. has already reached an agreement with Mallinckrodt allowing Actavis to launch a generic formulation of Exlago for the 8, 12, and 16 mg dosage strengths back in November 2013. The agreement allows for Actavis to launch a generic 32 mg dosage strength on May 15, 2014. Under terms of the previous agreement with Mallinckrodt, Zalicus royalties on net sales of the approved dosage strengths are reduced by 50% upon the introduction of generic versions of the drug.
...Uses Cash to Strengthen Balance Sheet...
Our financial model assumed only limited royalties on sales of Exalgo to Zalicus in 2014, so the $7.2 million in cash received by Zalicus on January 31, 2014 was a nice positive surprise. Zalicus immediately used the $7.2 million cash payment from Mallinckrodt to pay off an $8.65 million outstanding term loan with Oxford Finance LLC. The original $20 million loan was entered into back in December 2010 with Oxford. Zalicus paid both principal and interest payments on the loan in 2013, with another $6.7 million due in 2014 and $2.1 million scheduled for 2015 assuming full interest payments were made. Paying down the loan in its entirety not only improves the company's working-capital position, but also reduces future cash burn associated with the principal and interest payments.
As a result of paying back the loan, Oxford has released all security interests in Zalicus' tangible and intangible property. This should allow the company to enter into future equity or debt financings unencumbered by the terms of the Oxford transaction.
Zalicus reported cash and equivalents at December 31, 2013 of $19.8 million. We note net cash burn in the fourth quarter 2013 was only $0.2 million, as the company raised $7.7 million in cash through sales of securities to Lincoln Park Capital in October 2013. As of October 24, 2013, Zalicus has sold $19.8 million of the $25.0 million allowed through the securities purchase agreement with Lincoln Park. We believe the company's goal is to keep cash and cash equivalents of - at least - six months of operating burn. For the first half of 2014, we model cash usage from operations of roughly $10 million, meaning Zalicus should tap the remaining $5.2 million from Lincoln Park here in the first or second quarter 2014 (assuming they haven't already done so). We model cash at March 31, 2014, the end of the first quarter, to still be above $17.5 million.
Z944 Is the Primary Driver In 2014
Given the failure of Z160 in November 2013, all eyes are now squarely focused on Z944 as the primary valuation driver in 2014 and beyond. Z944 is the company's novel, oral T-type calcium channel (Cav 3.1, Cav 3.2, and Cav 3.3) modulator for chronic, acute, or visceral pain. The profile of the drug candidate clearly has enormous potential for Zalicus, but it is early stage, having only just recently completed a Phase 1b study in November 2013.
The preclinical data generated to date with Z944 is very encouraging. In February 2012, the company published a paper in Science Translational Medicine identifying Z944 as a potential therapy for seizure and generalized epilepsy. In May 2013, the company presented Poster #383 at the American Pain Society highlighting the mechanism of action for Z944 and its potential utility in various nonclinical models of acute and inflammatory pain. Below we highlight some of this data showing how Z944 compared well to naproxen in rat complete Freund's adjuvant (CFA) model, mouse formalin model, and in a model of rat visceral pain.
(click to enlarge)
The Phase 1b data has some good nuggets of information. Firstly, Zalicus saw dose proportional pharmacokinetics with similar exposure to preclinical doses where efficacy was achieved. The data show rapid absorption and a pk profile that supports twice daily dosing. The drug was also well tolerated, but the company did identify a maximum tolerated dose. In fact, when doses got too high there were limiting CNS side effects. This is in contrast to Z160 where Zalicus saw very limited side effects and incredible tolerability. It's important to note companies want to see dose-limiting CNS side effects. That confirms the drug is hitting the target organ. With Z160, no dose-limiting side effects should have been a clue that the efficacy wasn't there.
The Phase 1b study utilized a state-of-the-art experimental clinical model measuring Laser-Evoked Potentials (LEP) following administration of capsaicin or exposure to UV light. The trial was designed to efficiently provide objective and subjective data on a drug's ability and modulate neuropathic pain signaling. This provided management with a better sense of the efficacy signal than with Z160. Data shows that Z944 reduced peak-to-peak amplitudes in both neuropathic (capsaicin) and inflammatory (UV) pain models (see graphs below taken from the company's investor presentation). The drug also reduced subjective VAS pain scores for both models, with the highest dose of 80mg comparing well to preclinical data on Pfizer's (PFE) Lyrica (pregabalin).
GOOD NEWS. The company received 7 million dollar.
(Look latest 8K).
I'm avrg down.
It wasn't a good id , I hope it spikes again soon.
Going down after good news. Do I miss something?
Forming a new bottom at 1.5$ Imo
Disappointed and dumped it just in time
Got a little over extended on the run-up. MM's pushed it lower to cover their shorts hit the trendline at 1.74 and bounced back. We should start a nice stepping pattern. The weekly chart is heavely bullish!!
What did I tell you all! WEEEEEEE $$$$$$$$$$ See ya at 2.50 then 3.00
Oh sorry. Thought this was another stock. I'm not it it now but I want back in. Kinda mad I sold my shares. I'm looking for a bounce play.
Did you buy that spike about a week ago? I think we're going to get another one soon and then it will be a multi day green up to resistance around $3.50. We shall see.
I got it at 1.90 should have waited to 1.50 oh well
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2191
|
Created
|
08/12/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=ZLCS
http://www.form4oracle.com/company?cik=0001135906&ticker=crxx
Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinson's disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. on September 9, 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |